Mark R. Ziebell
2017
In 2017, Mark R. Ziebell earned a total compensation of $581K as Vice President, General Counsel and Corporate Secretary at Peregrine Pharmaceuticals, a 1% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $112,704 |
|---|---|
| Option Awards | $62,850 |
| Salary | $361,385 |
| Other | $44,074 |
| Total | $581,013 |
Ziebell received $361.4K in salary, accounting for 62% of the total pay in 2017.
Ziebell also received $112.7K in non-equity incentive plan, $62.9K in option awards and $44.1K in other compensation.
Rankings
In 2017, Mark R. Ziebell's compensation ranked 11,319th out of 14,666 executives tracked by ExecPay. In other words, Ziebell earned more than 22.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,319 out of 14,666 | 23rd |
Division Manufacturing | 4,435 out of 5,768 | 23rd |
Major group Chemicals And Allied Products | 1,611 out of 2,074 | 22nd |
Industry group Drugs | 1,328 out of 1,730 | 23rd |
Industry Pharmaceutical Preparations | 1,038 out of 1,329 | 22nd |
Source: SEC filing on August 17, 2018.
Ziebell's colleagues
We found three more compensation records of executives who worked with Mark R. Ziebell at Peregrine Pharmaceuticals in 2017.
News
Peregrine Pharmaceuticals CEO Nicholas Green's 2023 pay rises 5% to $6.5M
August 28, 2023
Peregrine Pharmaceuticals CEO Nicholas Green's 2022 pay jumps 117% to $6.2M
August 29, 2022
Peregrine Pharmaceuticals CEO Nicholas Green receives $2.8M in 2021
August 27, 2021
Peregrine Pharmaceuticals General Counsel Mark Ziebell's 2020 pay jumps 124% to $1.1M
August 27, 2020
Peregrine Pharmaceuticals CEO Roger Lias' 2019 pay jumps 25% to $880K
August 21, 2019
Peregrine Pharmaceuticals CEO Roger Lias receives $704K in 2018
August 17, 2018